Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065697 | 0.84 | ALDH1A1 (0.40) | ALDH1A1POLBKMT2ATLR8CYP19A1 | |
| SCHEMBL9026376 | 0.78 | AGTR1 (0.40) | ALDH1A1POLBKMT2ADGAT1TLR8 | |
| SCHEMBL1126106 | 0.75 | TLR8 (0.47) | ALDH1A1POLBKMT2ADGAT1TLR8 | |
| SCHEMBL30944028 | 0.75 | DGAT1 (0.34) | DGAT1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9638271 | 0.75 | DGAT1 (0.41) | ALDH1A1POLBKMT2ADGAT1 | |
| SCHEMBL18038297 | 0.74 | KMT2A (0.42) | ALDH1A1POLBKMT2ATLR8CYP19A1 | |
| SCHEMBL9592717 | 0.74 | KCNH2 (0.37) | ALDH1A1POLBKMT2ADGAT1TLR8 | |
| SCHEMBL32681724 | 0.74 | DGAT1 (0.36) | ALDH1A1POLBKMT2ADGAT1TLR8 | |
| SCHEMBL18547810 | 0.73 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL1488779 | 0.73 | KMT2A (0.43) | ALDH1A1POLBKMT2ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-01 | — | — | US | disclosed |
| EP-4305040-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022189387-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-15 | — | — | WO | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CDK2, CCNK | ALDH1A1 2910/4885POLB 164/4885KMT2A 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.